Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas

Abstract

Clinical outcome in diffuse large B-cell lymphoma (DLBCL) remains unpredictable, despite the identification of clinical prognostic parameters. Here, we investigated in pretreatment biopsies of 70 patients with DLBCL whether numbers of activated cytotoxic T-lymphocytes (CTLs), as determined by the percentage of CD3-positive lymphocytes with granzyme B (GrB) expression, have similar prognostic value as found earlier in Hodgkin's lymphoma and anaplastic large-cell lymphoma and whether loss of major histocompatibility complex (MHC)-I molecules or expression of the GrB antagonist protease inhibitor 9 (PI9) may explain immune escape from CTL-mediated cell death. Independent of the International Prognostic Index (IPI), the presence of 15% activated CTLs was strongly associated with failure to reach complete remission, with a poor progression-free and overall survival time. Downregulation of MHC-I light- and/or heavy-chain expression was found in 41% of interpretable cases and in 19 of 56 interpretable cases PI9 expression was detected. We conclude that a high percentage of activated CTLs is a strong, IPI independent, indicator for an unfavorable clinical outcome in patients with primary nodal DLBCL. Although in part of DLBCL expression of PI9 and loss of MHC-I expression was found, providing a possible immune-escape mechanism in these cases, no correlation with clinical outcome was found.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.

  2. Jaffe ES, Harris NL, Stein H, Vardiman JW . Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. World Health Organisation Classification of Tumors. Lyon: IARC Press, 2001.

    Google Scholar 

  3. The International Non-Hodgkin's Lymphomas Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994.

  4. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 1376–1382.

    CAS  PubMed  Google Scholar 

  5. Ten Berge RL, Dukers DF, Oudejans JJ, Pulford K, Ossenkoppele GJ, de Jong D et al. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999; 93: 2688–2696.

    CAS  PubMed  Google Scholar 

  6. Johnstone RW, Ruefli AA, Lowe SW . Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153–164.

    Article  CAS  PubMed  Google Scholar 

  7. Barry M, Bleackley RC . Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002; 2: 401–409.

    Article  CAS  PubMed  Google Scholar 

  8. Darmon AJ, Nicholson DW, Bleackley RC . Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377: 446–448.

    Article  CAS  PubMed  Google Scholar 

  9. Darmon AJ, Ley TJ, Nicholson DW, Bleackley RC . Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. J Biol Chem 1996; 271: 27109–27112.

    Google Scholar 

  10. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L . Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998; 8: 451–460.

    Article  CAS  PubMed  Google Scholar 

  11. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR et al. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members Bid en Bax. J Exp Med 2000; 192: 1391–1401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Monaco JJ . A molecular model MHC class-I-restricted antigen presentation. Immunol Today 1992; 13: 173–179.

    Article  CAS  PubMed  Google Scholar 

  13. Rees C, Mian S . Selective MHC expression in tumors modulates adaptive and innate antitumor responses. Cancer Immunol Immunother 1999; 48: 374–381.

    Article  CAS  PubMed  Google Scholar 

  14. Riemersma SA, Jordanova ES, Schop RFJ, Philippo K, Looijenga LHJ, Schuuring E et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000; 96: 3569–3577.

    CAS  PubMed  Google Scholar 

  15. Frisan T, Zhang QJ, Levitskaya J, Coram M, Kurilla MG, Masucci MG . Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Int J Cancer 1996; 68: 251–258.

    Article  CAS  PubMed  Google Scholar 

  16. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, Baak JP et al. Analysis of major histocompatibility complex class I expression in Reed–Sternberg cells in relation to the cytotoxic T-cell response in Epstein–Barr virus positive and negative Hodgkin's disease. Blood 1996; 87: 38–44.

    Google Scholar 

  17. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF . Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein–Barr virus-positive Hodgkin's disease. Blood 1998; 92: 2477–2483.

    CAS  PubMed  Google Scholar 

  18. Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18: 6387–6398.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sun J, Bird CH, Sutton V, Coughlin PB, De Jong TA, Trapani JA et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802–27809.

    Article  CAS  PubMed  Google Scholar 

  20. Bladergroen BA, Meijer CJLM, Ten Berge RL, Hack CE, Muris JJF, Dukers DF et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with Hodgkin's and non-Hodgkin's lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002; 99: 232–237.

    Article  CAS  PubMed  Google Scholar 

  21. Gospodarowicz MK, Sutcliffe SB . The extranodal lymphomas. Semin Radiat Oncol 1995; 4: 281–300.

    Article  Google Scholar 

  22. Kummer JA, Kamp AM, van Katwijk M, Brakenhoff JP, Radosevic K, van Leeuwen AM et al. Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods 1993; 163: 77–83.

    Article  CAS  PubMed  Google Scholar 

  23. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL . HLA-A and HLA-B-specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin fixed, paraffin embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 113–125.

    Article  CAS  PubMed  Google Scholar 

  24. Polkowski W, Meijer GA, Baak JP, ten Kate FJ, Obertop H, Offerhaus GJ et al. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus. Anal Quant Cytol Histol 1997; 19: 246–254.

    CAS  PubMed  Google Scholar 

  25. Cox DR . Regression models and life tables. J R Stat Soc Br 34; 187: 1972.

    Google Scholar 

  26. Armitage JO . Weisenberger DD for the non-Hodgkin's lymphoma classification project. New approach to classifying non-Hodgkin's lymphomas. Clinical features of the major histologic subtypes. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  PubMed  Google Scholar 

  27. Schmitt CA, Lowe SW . Apoptosis and therapy. J Pathol 1999, 127–137.

  28. Friesen C, Herr I, Krammer PH, Debatin KM . Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574–577.

    Article  CAS  PubMed  Google Scholar 

  29. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM . Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases 9 ICE/Ced-3 proteases). Blood 1997; 90: 3118–3129.

    CAS  PubMed  Google Scholar 

  30. Friesen C, Fulda S, Debatin KM . Induction of CD95 ligand and apoptosis by doxirubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 1999; 6: 471–480.

    Article  CAS  PubMed  Google Scholar 

  31. Boesen-de Cock JG, Tepper AD, de Vries E, van Blitterswijk WJ, Borst J . Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J Biol Chem 1999; 274: 14255–14261.

    Article  CAS  PubMed  Google Scholar 

  32. Felgar RE, Greer JP, Macon W . T-cell-rich large-B-cell lymphoma (TCRBCL) as compared to diffuse large-B-cell lymphoma [letter]. Am J Pathol 1998; 153: 1707–1715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wolkers MC, Stoetter G, Vyth-Dreese FA, Schumacher TNM . Redundancy of direct priming and cross-priming in tumor specific CD8+ T cell responses. J Immunol 2001; 67: 3577–3584.

    Article  Google Scholar 

  34. Heath WR, Carbone FR . Cross-presentation, dendritic cells, tolerance and immunity [review]. Annu Rev Immunol 2001; 19: 47–64.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J J Oudejans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muris, J., Meijer, C., Cillessen, S. et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18, 589–596 (2004). https://doi.org/10.1038/sj.leu.2403240

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403240

Keywords

This article is cited by

Search

Quick links